Status:
RECRUITING
Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
Lead Sponsor:
Vastra Gotaland Region
Conditions:
Proliferative Diabetic Retinopathy
Diabetic Retinopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical...
Detailed Description
Proliferative diabetic retinopathy (PDR) is a well-known complication for both type 1 and type 2 diabetes mellitus (DM) and it is the leading cause for blindness in working-age adults. The current gol...
Eligibility Criteria
Inclusion
- Age \> 18 years.
- Patients with type 1 or type 2 Diabetes Mellitus with newly diagnosed Proliferative Diabetic Retinopathy, PDR.
- Visual acuity ≥ 0.1 Snellen.
- CRT of less than 300 micrometer measured by OCT without cysts in the neuroretina.
- Clear media and adequately dilated pupil for PRP.
Exclusion
- Intraocular surgery within the last 4 months or planned within the next 3 months.
- Previous or current center-involved diabetic macular edema (Ci-DME).
- Previous PRP, intravitreal treatment (IVT), or macular laser treatment in study eye.
- Treatment with medications known to risk macular edema.
- Media opacity preventing adequate PRP.
- General medical condition making office laser treatment very difficult or impossible.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06549023
Start Date
January 1 2025
End Date
December 31 2030
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ögonmottagning Mölndal/SU
Mölndal, Sweden, 43130